You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Why DTG + RPV?

Dolutegravir and Rilpivirine: An Innovative Pairing

Like traditional 3-drug regimens, dolutegravir + rilpivirine inhibits the viral life cycle at 2 different targets [1],[2]

DTG + RPV is a effective treatment regimen

See why the pairing of DTG + RPV is an effective choice for a 2DR

References:

  1. Tivicay▼ (dolutegravir) Summary of Product Characteristics. Available from: www.medicines.ie. Last accessed: October 2018.
  2. Rilpivirine Summary of Product Characteristics. Available from: www.medicines.ie. Last accessed: October 2018.
  3. Walmsley S et al. J Acquir Immune DeficSyndr. 2015;70:515-519.
  4. Molina J-M et al. Lancet HIV. 2015;2(4):e127-e136.
  5. Orrell C et al. Lancet HIV. 2017;4:e536-e546.
  6. Aboud M et al. Presented at: Annual International AIDS Conference; July 23-26, 2017; Paris, France.
  7. Cahn P et al. Lancet. 2013;382(9893):700-708.
  8. Raffi F et al. Lancet Infect Dis. 2013;13(11):927-935.
  9. Triumeq▼ (dolutegravir/abacavir/lamivudine) Summary of Product Characteristics. Available from: www.medicines.ie. Last accessed: October 2018.
  10. Pozniak AL et al. AIDS. 2010;24:55-65.
  11. Mills AM et al. HIV Med. 2014;14:391-400.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.